MedTrace Logo

Diagnostic and Prognostic Value of PTEN Expression in Functional and Pathological Endometrial Biopsies

NCT04873206 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-07-15

No results posted yet for this study

Summary

endometrial hyperplasia may progress to endometrial adenocarcinoma. the exact possibility of such progression is not determined. there a need to detect biological markers that can help in detecting high risk cases of patients with endometrial hyperplasia that may progress to endometrial adenocarcinoma. PTEN is a tumor suppressor gene that inhibit cell migration, proliferation and may induce apoptosis in damaged cells. variable expression of PTEN in functional, hyperplastic and neoplastic endometrial tissues may be of great help in detecting cases of hyperplasia that may progress to endometrial adenocarcinoma.

Conditions

  • Endometrial Hyperplasia
  • Endometrial Adenocarcinoma

Interventions

OTHER

routine stain by H&E.

formalin fixed, Parraffin embedded endometrial tissues will be sectioned and get stained by the routine Haematoxalin and Eosin stain in addition to immunohistochemical staining by anti-human PTEN antibody.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Maisa H Mohammed, MD · a lecturer of pathology, Sohag faculty of medicine

Eligibility

Min Age
15 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04873206 on ClinicalTrials.gov